Data collected on risk factors are shown in Table 1. The median age was 67 years (IQR 59–74) and the median time from the heart transplant was 12 years (IQR 4–17.5). Among the patients’ risk factors arterial hypertension was the most frequent, occurring in 83%, followed by dyslipidaemia in 50%. Only 1 patient was obese. The median glomerular filtration rate was 92 ml/min (IQR 79–133); no patients needed dialysis. At the last follow-up, all patients were classified as New York Heart Association functional class I with the exception of 1 in functional class II. One patient had a previous percutaneous coronary intervention procedure for a cardiac allograft vasculopathy. Graft function was preserved in all patients as evidenced by the last echocardiographic follow-up with a median left ventricular ejection fraction of 56% (IQR 53–58). Only 1 patient had a history of cellular-mediated rejection graded as moderate, 2R according to the International Society of Heart and Lung Transplantation classification of 2004, obtained in October 1997. Immunosuppressive therapy included cyclosporine for all patients, associated with mycophenolate in 4 cases and everolimus in 1 case.